Cogstate

We at Cogstate would like to express how deeply saddened we were to learn of the sudden passing of Bruce Albala, who served as a member of the Cogstate scientific advisory board. Across the past 15 years, Bruce has been our customer, collaborator, confidant, counsel and most importantly, incredibly dear friend. "Bruce was a man with big ideas, large expectations, and a massive heart. He dedicated his scientific life to seeking a cure for Alzheimer’s disease. The field is poorer, and certainly quieter, with his passing," noted his friend, Paul Maruff (Cogstate CIO). We feel Bruce's absence particularly strongly at this time when industry colleagues meet for the CTAD conference, which Bruce regularly attended. "Bruce, see you later old buddy. We will seek to honor you and our relationship with you by continuing the fight with your commitment and zeal," Maruff shared in a brief memorial post that can be read here: https://lnkd.in/e4muuEut Our deepest condolences go out to Bruce's wife and daughters at this tremendously difficult time.

Cogstate and Medidata Solutions are pleased to announce a strategic collaboration to address the complexities of CNS clinical trials by delivering a fully unified platform for assessment delivery and oversight. “The ability to deliver precise and reliable data is critical for understanding and treating complex neurological conditions,” said Brad O'Connor, CEO, Cogstate. “The strategic combination of science and technology available in the Cogstate and Medidata partnership allows us to deliver unique data quality innovations for more informed clinical trial decision-making and better patient outcomes.” Read more about the partnership here: https://lnkd.in/dc5i8iUR

Cogstate's team of Alzheimer's Disease experts are packing up for #CTAD24 in Madrid! We look forward to the opportunity to gather with colleagues and discuss new results and developments in the next generation of Alzheimer’s disease treatments. In particular, our core science team is thrilled to now also include AD industry experts Kaycee Sink, MD, MAS and Annamarie Vogt PhD who will be meeting with clinical trial leaders during the event. Book time to meet up with our experts today: https://lnkd.in/eeewYn4p

Clinical meaningfulness using the PACC, mapping AD progression via the CDR, effect of baseline amyloid level on cognitive decline... Cogstate scientists will be discussing these topics and more during scientific presentations at #CTAD24 in Madrid. Will your team be there too? Let us know! Check out Cogstate's full presentation list or request an in-person meeting here: https://lnkd.in/eeewYn4p

We are delighted to announce the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer! In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. “Cogstate’s commitment to bring technology and science to improve brain health assessment and to look at Alzheimer’s disease in a holistic manner is very exciting,” said Dr. Sink. “I’m thrilled to join this team of scientific and operational experts and contribute my passion to the evolving healthcare and research landscape in support of getting the right treatment to the right patients at the right time.” Dr. Sink is board certified in Internal Medicine and Geriatric Medicine with over 20 years of experience in clinical care and research in aging, Alzheimer’s disease, and other neurodegenerative disorders. READ THE FULL PRESS RELEASE HERE > https://lnkd.in/gqUAvJtR

Clinical trials in patients with rare epilepsy disorders present significant challenges for research teams, including patient identification, site selection, and precise measurement needs. Join Dr. Pam Ventola, Cogstate CSO and Yale Associate Professor, as she provides details to help your team: ▪️ Collect data across large geographic areas ▪️ Approach locations that may not have specialized raters ▪️ Select appropriate cognitive and behavioral endpoints ▪️ Consider approaches to determine MCID 📅 October 3, 2024 | 11am EST ➡️ Register to attend: https://lnkd.in/eHHCMvhn

Lessons from the TRAILBLAZER-ALZ-2 Rater Performance Central Monitoring Program > Data shared in a poster co-authored by Cogstate highlight learnings from a rater performance monitoring program used in the TRAILBLAZER-ALZ 2 Randomized Clinical Trial of Donanemab in Early Symptomatic Alzheimer Disease. Rater performance was analyzed across four outcome measures that were part of the study and are frequently leveraged in AD clinical trials: ADAS-Cog 13, ADCS-ADL, CDR, and MMSE. See the findings and the poster in this article (click link or image below)!

Making decisions about dosing, mechanism of action, and length of effect in sleep medicine can all be better informed when using cognitive assessments.  In this short whitepaper, Professor Paul Maruff, Chief Innovation Officer at Cogstate, uses case examples from clinical trials we’ve supported to explore insights and methodologies that can help clinical trial teams improve decision-making in this area. Find methodologies to bolster your safety and efficacy decisions in sleep-related trials: https://lnkd.in/ecNzqAFG

🌱🌿 Some of the proud “plant parents” here at Cogstate! One of the many perks of a virtual-first policy is the ability to make our workspaces as unique as we are, including an abundance of plants (if we so choose). Whether we display bouquets from our kids, chill with a poisonous cactus, or take a coffee break in a thriving outdoor space, we’re basking in our remote work life! Without fail, ‘remote working’ questions in our Cogstate team member surveys are one of the highest scoring factors. We’ve leaned into this model and are loving the results--happy employees and continued positive business outputs.

Cognitive measurement can be used to understand effects of medicines used to optimize sleep or wakefulness. In this short video, Cogstate CIO, Paul Maruff, answers questions about this topic, including: •Can the sedative effects of drugs like benzodiazepines observed in healthy young adults help estimate their impact on older adults? •How do these sedative effects translate across different patient populations? •Is the fatigue reported by people with MS similar to that experienced by individuals with Parkinson’s disease? And can the same wake-promoting drugs be effective in both groups? 📺 Gather his thoughts on YouTube 👉 https://lnkd.in/eg5FWjhf